Brief: Medicinova Receives Notice Of Allowance For New Patent For The Treatment Of Amyotrophic Lateral Sclerosis In Canada
11/10/2023 24:04
Oct 10 (Reuters) - MediciNova Inc MNOV.O :
* MEDICINOVA RECEIVES A NOTICE OF ALLOWANCE FOR A NEW PATENT
COVERING THE COMBINATION OF MN-166 (IBUDILAST) AND RILUZOLE FOR
THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN CANADA
* ONCE ISSUED, PATENT MATURING FROM THIS ALLOWED PATENT
APPLICATION IS EXPECTED TO EXPIRE NO EARLIER THAN NOVEMBER 2035
Source text for Eikon: ID:nGNX7SmXbF
Further company coverage: MNOV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake